Amgen Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products

We are pleased to have reached resolution of our patent infringement litigation related to Fresenius’s denosumab biosimilar products in the United States. In addition, the parties’ global confidential settlement allows Fresenius to launch its biosimilar products in the U.S. as early as June 30, 2025, and in Europe in November 2025. Specific financial terms remain confidential. The resolution affirms the strength of Amgen's patent rights for denosumab.